We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
Read MoreHide Full Article
Key Takeaways
Eli Lilly reached an all-time high after Jaypirca's positive CHMP opinion and Medicare pricing updates.
LLY's Jaypirca label expansion filing now heads to the EC after CHMP backed broader CLL use.
Eli Lilly will offer eligible Medicare Part D patients Zepbound and Foundayo for $50 monthly.
Shares of Eli Lilly (LLY - Free Report) rose more than 7% on Friday after the company announced several positive developments related to its marketed products.
An EMA advisory committee recommended approving the company’s filing seeking label expansion for the oncology drug Jaypirca (pirtobrutinib) to treat adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.
The momentum was further boosted after Lilly announced that its popular obesity drugs, Zepbound and Foundayo, will be available via Medicare for $50 per month starting from July 1, 2026.
LLY Stock Performance
Following these announcements, Lilly's shares climbed to an all-time high of $1,215.76. While neither development materially changes the company's near-term outlook, both strengthen its long-term growth prospects. Expanded Medicare access to its obesity drugs could improve patient affordability and support continued growth for its blockbuster metabolic franchise. Meanwhile, the positive recommendation for Jaypirca not only strengthens Lilly's oncology portfolio but also diversifies its growth across therapeutic areas.
Year to date, the stock has risen 12.4% compared with the industry’s 11.6% growth.
Image Source: Zacks Investment Research
CHMP Backs Lilly’s Filing for Jaypirca Label Expansion
Jaypirca is currently approved in the European Union to treat adult patients with relapsed or refractory CLL who have been previously treated with a BTK inhibitor. The latest CHMP opinion supports expanding its use to adults with CLL across all lines of therapy, regardless of prior BTK inhibitor treatment, significantly broadening the drug's potential patient population.
Lilly’s regulatory filing has now been referred to the European Commission (“EC”), with a final decision expected within the next one to two months. While the EC is not obligated to follow the CHMP's recommendation, it generally does.
The positive opinion is supported by positive data from two late-stage studies. One study evaluated Jaypirca against a chemoimmunotherapy regimen (bendamustine plus rituximab) in treatment-naïve CLL patients. The other compared Lilly’s cancer pill with AbbVie’s (ABBV - Free Report) /J&J’s (JNJ - Free Report) Imbruvica (ibrutinib) in treatment-naïve patients as well as previously treated patients who were BTK inhibitor-naïve. A similar regulatory filing is also under review with the FDA, with a final decision expected before this year’s end.
Medicare Access Expands Reach of Lilly's Obesity Drugs
Lilly also announced that eligible Medicare Part D beneficiaries prescribed Zepbound or Foundayo for obesity will be able to access the medicines for $50 per month starting next month. The initiative is aimed at improving affordability and expanding access to the company's two obesity drugs, the once-weekly injection Zepbound and daily pill Foundayo.
The move could further strengthen Lilly's competitive position against Novo Nordisk (NVO - Free Report) , which markets Wegovy in both injectable and oral formulations. While Lilly's obesity therapies have demonstrated superior efficacy in clinical studies, NVO's Wegovy products have a longer commercial track record and a well-established safety and tolerability profile. By improving affordability for Medicare beneficiaries, Lilly could further expand the reach of its obesity franchise in an increasingly competitive market. The company estimates that 20 million Medicare patients could meet clinical criteria for obesity medicines.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
Key Takeaways
Shares of Eli Lilly (LLY - Free Report) rose more than 7% on Friday after the company announced several positive developments related to its marketed products.
An EMA advisory committee recommended approving the company’s filing seeking label expansion for the oncology drug Jaypirca (pirtobrutinib) to treat adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.
The momentum was further boosted after Lilly announced that its popular obesity drugs, Zepbound and Foundayo, will be available via Medicare for $50 per month starting from July 1, 2026.
LLY Stock Performance
Following these announcements, Lilly's shares climbed to an all-time high of $1,215.76. While neither development materially changes the company's near-term outlook, both strengthen its long-term growth prospects. Expanded Medicare access to its obesity drugs could improve patient affordability and support continued growth for its blockbuster metabolic franchise. Meanwhile, the positive recommendation for Jaypirca not only strengthens Lilly's oncology portfolio but also diversifies its growth across therapeutic areas.
Year to date, the stock has risen 12.4% compared with the industry’s 11.6% growth.
Image Source: Zacks Investment Research
CHMP Backs Lilly’s Filing for Jaypirca Label Expansion
Jaypirca is currently approved in the European Union to treat adult patients with relapsed or refractory CLL who have been previously treated with a BTK inhibitor. The latest CHMP opinion supports expanding its use to adults with CLL across all lines of therapy, regardless of prior BTK inhibitor treatment, significantly broadening the drug's potential patient population.
Lilly’s regulatory filing has now been referred to the European Commission (“EC”), with a final decision expected within the next one to two months. While the EC is not obligated to follow the CHMP's recommendation, it generally does.
The positive opinion is supported by positive data from two late-stage studies. One study evaluated Jaypirca against a chemoimmunotherapy regimen (bendamustine plus rituximab) in treatment-naïve CLL patients. The other compared Lilly’s cancer pill with AbbVie’s (ABBV - Free Report) /J&J’s (JNJ - Free Report) Imbruvica (ibrutinib) in treatment-naïve patients as well as previously treated patients who were BTK inhibitor-naïve. A similar regulatory filing is also under review with the FDA, with a final decision expected before this year’s end.
Medicare Access Expands Reach of Lilly's Obesity Drugs
Lilly also announced that eligible Medicare Part D beneficiaries prescribed Zepbound or Foundayo for obesity will be able to access the medicines for $50 per month starting next month. The initiative is aimed at improving affordability and expanding access to the company's two obesity drugs, the once-weekly injection Zepbound and daily pill Foundayo.
The move could further strengthen Lilly's competitive position against Novo Nordisk (NVO - Free Report) , which markets Wegovy in both injectable and oral formulations. While Lilly's obesity therapies have demonstrated superior efficacy in clinical studies, NVO's Wegovy products have a longer commercial track record and a well-established safety and tolerability profile. By improving affordability for Medicare beneficiaries, Lilly could further expand the reach of its obesity franchise in an increasingly competitive market. The company estimates that 20 million Medicare patients could meet clinical criteria for obesity medicines.
Eli Lilly and Company Price
Eli Lilly and Company price | Eli Lilly and Company Quote
LLY Zacks Rank
Eli Lilly currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.